BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38925607)

  • 1. The protective effect of vitamin D on ovarian reserve and anti-mullerian hormone in patients undergoing chemotherapy for breast cancer, a randomized phase ΙΙ clinical trial.
    Dastmardi Z; Lashkari M; Saeedian A; Aghili M; Alipour S
    Cancer Rep (Hoboken); 2024 Jun; 7(6):e2104. PubMed ID: 38925607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of serum vitamin D levels on ovarian reserve markers: a prospective cross-sectional study.
    Drakopoulos P; van de Vijver A; Schutyser V; Milatovic S; Anckaert E; Schiettecatte J; Blockeel C; Camus M; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Jan; 32(1):208-214. PubMed ID: 27927849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Association between Vitamin D and Anti-Müllerian Hormone: A Systematic Review and Meta-Analysis.
    Moridi I; Chen A; Tal O; Tal R
    Nutrients; 2020 May; 12(6):. PubMed ID: 32481491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
    Wang S; Pei L; Hu T; Jia M; Wang S
    Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients].
    Wang SY; Wang S
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
    Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
    BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.
    Hamy AS; Porcher R; Cuvier C; Giacchetti S; Schlageter MH; Coussieu C; Gronier H; Feugeas JP; Adoui N; Lacorte JM; Poirot C; Habdous M; Espié M
    Reprod Biomed Online; 2014 Nov; 29(5):573-80. PubMed ID: 25246112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of vitamin D supplementation on ovarian reserve markers in infertile women with diminished ovarian reserve.
    Bacanakgil BH; İlhan G; Ohanoğlu K
    Medicine (Baltimore); 2022 Feb; 101(6):e28796. PubMed ID: 35147111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year study assessing the clinical utility of anti-Müllerian hormone measurements in reproductive-age women with cancer.
    Palinska-Rudzka KE; Ghobara T; Parsons N; Milner J; Lockwood G; Hartshorne GM
    Reprod Biomed Online; 2019 Oct; 39(4):712-720. PubMed ID: 31471141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian reserve in premenopausal women with breast cancer.
    Zong X; Yu Y; Chen W; Zong W; Yang H; Chen X
    Breast; 2022 Aug; 64():143-150. PubMed ID: 35691250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ovarian reserve before and after chemotherapy.
    Berjeb KK; Debbabi L; Braham M; Zemni Z; Chtourou S; Hannachi H; Hamdoun M; Ayadi M; Kacem K; Zhioua F; Fadhlaoui A; Bahri O; Chakroun N
    J Gynecol Obstet Hum Reprod; 2021 May; 50(5):102035. PubMed ID: 33307239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-Dense Chemotherapy Regimen for Breast Cancer Associated with Significant Decline in Ovarian Reserve.
    Chamani IJ; Gannon A; Connell PT; Bisen A; Kovanci E; Sangi-Haghpeykar H; Woodard T; McKenzie LJ
    J Adolesc Young Adult Oncol; 2024 Jun; 13(3):465-468. PubMed ID: 38112555
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
    Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V
    Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer.
    Perdrix A; Saint-Ghislain M; Degremont M; David M; Khaznadar Z; Loeb A; Leheurteur M; Di Fiore F; Clatot F
    Reprod Biomed Online; 2017 Oct; 35(4):468-474. PubMed ID: 28652099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [An experiment control study on the ovarian reserve function after cisplatin intraperitoneal or intravenous chemotherapy in rats model].
    Fan BZ; Xia H; Chu L; Tong XW
    Zhonghua Fu Chan Ke Za Zhi; 2017 Apr; 52(4):249-253. PubMed ID: 28441841
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma.
    Policiano C; Subirá J; Aguilar A; Monzó S; Iniesta I; Rubio Rubio JM
    J Assist Reprod Genet; 2020 Jul; 37(7):1755-1761. PubMed ID: 32488563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
    Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
    Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
    Fréour T; Barrière P; Masson D
    Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
    Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
    Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian reserve after treatment with alkylating agents during childhood.
    Thomas-Teinturier C; Allodji RS; Svetlova E; Frey MA; Oberlin O; Millischer AE; Epelboin S; Decanter C; Pacquement H; Tabone MD; Sudour-Bonnange H; Baruchel A; Lahlou N; De Vathaire F
    Hum Reprod; 2015 Jun; 30(6):1437-46. PubMed ID: 25801499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.